


WHAT IS CLAIMED IS:


1. 5-({2-[(4-[1-(2-Hydroxyethyl)piperidin-4-yl]phenyl}carbonyl)amino]pyridin-4-yl}oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide 1.5 succinate salt.

2. 5-({2-[(4-[1-(2-Hydroxyethyl)piperidin-4-yl]phenyl}carbonyl)amino]pyridin-4-yl}oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide 0.5 succinate salt.

3. A crystal of a salt consisting of 5-({2-[(4-[1-(2-hydroxyethyl)piperidin-4-yl]phenyl}carbonyl)amino]pyridin-4-yl}oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide represented by formula (I):



4. A crystal of a salt consisting of 5-({2-[(4-[1-(2-hydroxyethyl)piperidin-4-yl]phenyl}carbonyl)amino]pyridin-4-yl}oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide represented by formula (I):



and maleic acid.

5. A crystal of 5-((2-((4-(1-(2-hydroxyethyl)piperidin-4-yl)phenyl)carbonyl)amino)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide 1.5 succinate salt, having a diffraction peak at a diffraction angle ($2\theta \pm 0.2^\circ$) of 22.4° in a powder X-ray diffraction.

6. The crystal according to claim 5, having diffraction peaks at diffraction angles ($2\theta \pm 0.2^\circ$) of 22.4° , 25.3° and 23.3° in a powder X-ray diffraction.

7. A crystal (α) of 5-((2-((4-(1-(2-hydroxyethyl)piperidin-4-yl)phenyl)carbonyl)amino)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide 0.5 succinate salt, having a diffraction peak at diffraction angles ($2\theta \pm 0.2^\circ$) of 19.8° in a powder X-ray diffraction.

8. A crystal of 5-((2-((4-(1-(2-hydroxyethyl)piperidin-4-yl)phenyl)carbonyl)amino)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide maleate salt, having a diffraction peak at a diffraction angle ($2\theta \pm 0.2^\circ$) of 20.1° in a powder X-ray diffraction.

9. A crystal of 5-((2-((4-(1-(2-hydroxyethyl)piperidin-4-yl)phenyl)carbonyl)amino)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide 1.5 succinate salt, having peaks at chemical shifts (± 0.5 ppm) of 108.5ppm, 155.1ppm and 179.9ppm in a ^{13}C solid state NMR spectrum.

10. The crystal according to claim 9, having peaks at chemical shifts (± 0.5 ppm) of 27.1 ppm, 34.8 ppm, 108.5 ppm, 155.1 ppm and 179.9 ppm in a ^{13}C solid state NMR spectrum.

5 11. A crystal of 5-({2-[(4-[1-(2-hydroxyethyl)piperidin-4-yl]phenyl}carbonyl)amino]pyridin-4-yl}oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide 1.5 succinate salt, having a powder X-ray diffraction pattern as shown in Figure 1.

10 12. A pharmaceutical composition comprising the salt or crystal according to any one of claims 1 to 11 as an active ingredient.